Eupraxia Pharmaceuticals Inc
Eupraxia Pharmaceuticals has developed a novel platform that enables us to modulate drug release with precision. This ability allows us to tailor the profiles of proven drugs to improve safety, duration and efficacy. Our disruptive technology encapsulates pharmaceutical microparticles in a customizable polymer shell that can extend drug release from days to months. Starting with osteoarthritis (a degenerative joint disease), we are advancing a portfolio of drug candidates tailored to specific treatment needs in the areas of osteoarthritis, post-surgical pain, and anti-infectives against post-surgical infection. Our lead product candidate, EP-104IAR, is a locally delivered, sustained-release, non-opioid treatment for pain related to osteoarthritis, which has successfully completed a phase IIA clinical trial at sites in Canada and will next be entered into a large US clinical trial in Q3 2018.
Conference Objective
Continuing conversations and negotiations, and new conversations, with potential: licensees, strategic investors, financial investors, acquirers, and strategic partners. Also meetings with existing and new vendors for outsourced services
Partnering Objective
Agnostic discussions as to potential multiparty outlicensing territorially and by species (veterinary and human). To potentially include co-development and co-commercialisation
Delegate Contacts
Sam Mercer, BSc Biochemistry, has worked in pharma research and development for over 20 years, starting with investigational work supporting HAART therapy in HIV as a student and subsequently business development, proposals and contracts with a number of global Contract Research Organisations in the UK, US, and Canada. After global CROs Sam moved to strategic outsourcing and the negotiation of global vendor relationships for Roche in Basel, Switzerland, followed by Novartis also in Basel, CH. After returning to native Canada Sam worked in consulting for a number of early-stage software, hardware and assorted technology firms in management consulting before joining Eupraxia Pharmaceuticals in 2015 to look after external agreements, vendor management, and business development and licensing.
Eupraxia founder James Helliwell MD FRCPC has a specialization in anesthesiology. He also received sub-specialty training in cardiac anesthesiology and transplantation, and board certification in Perioperative Echocardiography. Prior to founding Eupraxia, he held a clinical practice at a quaternary academic cardiac center in St. Paul’s Hospital, Vancouver. He also served as Clinical Assistant Professor at the University of British Columbia in the Department of Anesthesiology, Pharmacology and Therapeutics. With an active interest in administration, systems analysis and public policy reform, James has held many positions of leadership, most recently the presidency of the provincial anesthesiology body in British Columbia. Eupraxia allows him to lead a progressive company dedicated to providing patients with innovative treatments to relieve suffering and improve lives.